We Can Now Show You Which Trials Are at Risk

ClinicalTrials.gov is a registry, not a monitor. It shows you the current state of a trial — today's status, today's completion date, today's enrollment target. What it does not show you is what those fields looked like last month. When a sponsor pushes a primary completion date out by two years, the registry simply displays the new date. The old one is gone, and so is the signal.

DataLookout has been taking a full daily snapshot of every trial we track since March. That history is what makes our newest feature possible. Trials at Risk surfaces a sponsor's active trials that are showing warning signs, with the before-and-after behind each one.

What the scan found

Across the active trials we track, here is what was showing at-risk signals as of June 5, 2026:

2,443

Active trials at risk

1,764

Completion dates pushed

254

Enrollment cut

587

Endpoints changed

Those 2,443 trials span 1,159 distinct lead sponsors — this is not a handful of outliers. 152 trials are showing more than one signal at the same time, and 289 have had their completion date pushed out by more than a full year. Every trial here is active (recruiting, active and not recruiting, not yet recruiting, or enrolling by invitation). Finished trials are never counted.

Why this is hard to see manually: none of these are headline events. There's no press release when a completion date moves or an enrollment target drops. The change posts quietly to ClinicalTrials.gov, the registry overwrites the old value, and unless you happened to record the previous number, the shift is invisible. Multiply that across a watchlist of competitors and it's impossible to track by hand.

The three signals

Trials at Risk watches for three specific, observable changes — all drawn from the trial's own record, not from any prediction or model:

Completion date pushed out

The primary completion date moved later by 30 days or more. The flagship delay signal — a program is taking longer than the sponsor last told the registry.

Enrollment cut

The enrollment target was revised downward. Often the first quiet sign a study is being scaled back or restructured.

Endpoint changed

A primary endpoint was modified. A change to what the trial is measuring — material context for anyone reading the eventual readout.

Each at-risk trial is ranked by the severity of its recent changes over a 90-day window, so a study that pushed its date by two years and cut enrollment surfaces above one with a single minor edit.

What it looks like on real trials

Here's the actual Trials at Risk view for one sponsor — Regeneron — with the exact changes as recorded on ClinicalTrials.gov:

DataLookout's Trials at Risk view for Regeneron Pharmaceuticals: 13 trials at risk, ranked by severity, each showing the recent change — a pushed completion date, cut enrollment, or a modified endpoint. — The Trials at Risk view for a single sponsor, ranked by severity of recent changes over a 90-day window. Active trials only — a finished trial is never counted.

To be clear about what this is — and isn't. An at-risk flag is an observation, not a prediction. We are not saying these trials will fail or terminate. We are saying their key parameters have moved recently, and that movement is worth knowing about if you're tracking the program. What it means is your call.

Who it's for

BD and competitive intelligence teams watching a competitor's pipeline — a slipping Phase 3 completion date changes when a readout (and a potential market entry) is likely to land.
Biotech investors tracking specific assets — a quiet enrollment cut or endpoint change is the kind of detail that rarely makes it into a press release.
Clinical operations teams benchmarking against competitive trials in the same indication.

Where to find it

Trials at Risk is live in the dashboard now. Pick a sponsor you follow, and the page surfaces that sponsor's at-risk trials, ranked by severity. Free accounts see a preview; the full list — every at-risk trial with the before-and-after behind each one — is included on the paid plans ($29 and $99 per month). As always, the underlying data is ClinicalTrials.gov, updated daily.

See which of your watched trials are at risk

Pick a sponsor and surface its trials showing warning signs, ranked by severity.

Get Started Free

Data & methodology: All figures from ClinicalTrials.gov, processed by DataLookout's daily snapshot pipeline. "At risk" counts active trials (overall status of Recruiting, Active not recruiting, Not yet recruiting, or Enrolling by invitation) with at least one of three changes recorded in the prior 90 days: a primary completion date moved later by 30+ days, a downward revision to the enrollment target, or a change to a primary endpoint. Finished trials are excluded. Counts are recomputed daily and reflect a point-in-time snapshot. Data current as of June 5, 2026.

External sources cited: None — all data is drawn directly from ClinicalTrials.gov trial records.

Crohn's and Colitis: The $18 Billion Bet on One New Drug Target